Favourable safety of NsGene's encapsulated cells in Alzheimer's
This article was originally published in Scrip
Executive Summary
A safety review of the first three Alzheimer's disease patients given NsGene's nerve-growth-factor secreting encapsulated cells has been favourable, and a further three patients have now be included in the Phase Ib clinical trial.